Drug Profile


Alternative Names: B663; Lamprene

Latest Information Update: 11 Mar 2016

Price : $50

At a glance

  • Originator University College Dublin
  • Developer Alliance Pharma plc; Novartis; University College Dublin; University of Pretoria
  • Class Antibacterials; Antileprotics; Phenazines
  • Mechanism of Action Adenosine triphosphatase inhibitors; DNA inhibitors; P-glycoprotein inhibitors; Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Leprosy
  • Phase II/III Tuberculosis
  • Discontinued Crohn's disease; Liver cancer

Most Recent Events

  • 11 Feb 2016 Phase-II/III clinical trials in Tuberculosis in Lithuania (PO) (EudraCT2015-004440-19)
  • 01 Apr 2003 No development reported - Phase-III for Crohn's disease in Australia (PO)
  • 01 Apr 2003 No development reported - Preclinical for Cancer in South Africa (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top